Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (6213)	2/23/1999 8:08:00 AM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Headline: Zonagen Announces Schering-Plough to Manufacture Vasomax ====================================================================== THE WOODLANDS, Texas--(BW HealthWire)--Feb. 23, 1999--Zonagen Inc. (NASDAQ:ZONA)(PCX:ZNG) today announced that Schering-Plough Corporation (NYSE:SGP) has notified the Company that it has exercised its right to begin manufacturing finished product for Vasomax(R). Vasomax(R) is Zonagen's rapidly disintegrating oral formulation of phentolamine mesylate for the treatment of male erectile dysfunction that is currently under regulatory review by the U.S. Food and Drug Administration and the Medicines Control Agency in the U.K. In November 1997 Zonagen entered into a worldwide sales and marketing agreement with Schering-Plough for Vasomax(R). Zonagen Inc. is engaged in the development of pharmaceutical products for the reproductive system, including sexual dysfunction, urology, contraception and fertility. Through its wholly owned subsidiary, Fertility Technologies Inc. (FTI), Zonagen sells devices, instruments and supplies to fertility specialists, obstetricians and gynecologists. A copy of this press release may be obtained via facsimile by dialing 1-888-329-0920 or via the Internet by accessing www.zonagen.com. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to those relating to the uncertainties of clinical trial results and FDA approval in the U.S., and approval of regulatory authorities in other jurisdictions, substantial dependence on one product, uncertainty of protection for patents and proprietary technology, limited sales and marketing experience and dependence on collaborators, manufacturing uncertainties and reliance on third parties, competition and technological change, and other risks identified in the Company's Annual Report on Form 10-K for the year ended December 31, 1997, as filed with the Securities and Exchange Commission. CONTACT: Zonagen Inc., The Woodlands Jean Anne Mire, 281/719-3491 KEYWORD: TEXAS INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1999, Business Wire